What is the appropriate gabapentin dosing regimen for an adult with chronic refractory cough, including adjustments for elderly patients and those with impaired renal function?

Gabapentin Dosing for Chronic Cough

For adults with chronic refractory cough, start gabapentin at 300 mg once daily and titrate upward by adding one additional 300 mg dose each day as tolerated, up to a maximum of 1800 mg/day divided into two doses. 1

Standard Dosing Regimen

The American College of Chest Physicians (CHEST) 2016 guideline provides the definitive dosing schedule for gabapentin in unexplained chronic cough 1:

• Day 1: 300 mg once daily
• Day 2: 300 mg twice daily (600 mg/day total)
• Day 3 onward: Continue adding 300 mg doses daily as tolerated
• Target dose: 1800 mg/day in two divided doses (900 mg twice daily)

This dose escalation schedule balances efficacy against side effects. The guideline emphasizes that gabapentin improves quality of life in patients whose chronic cough severely impacts daily functioning, with benefits outweighing potential adverse effects 1. The most common side effects include confusion, dizziness, dry mouth, fatigue, and nausea, occurring in approximately 31% of patients 1.

Critical requirement: Discuss the risk-benefit profile with patients before initiating therapy and reassess at 6 months before continuing treatment 1.

Renal Dose Adjustments

Gabapentin is exclusively eliminated by the kidneys, making dose adjustment mandatory in renal impairment 2, 3, 4. The FDA label provides specific dosing based on creatinine clearance 2:

Creatinine Clearance-Based Dosing:

• CrCl ≥60 mL/min: Standard dosing (300-1800 mg/day in divided doses)
• CrCl 30-59 mL/min: 400-1400 mg/day in two divided doses
  • Start 200 mg twice daily, titrate to 700 mg twice daily maximum
• CrCl 15-29 mL/min: 200-700 mg/day as single daily dose
  • Start 200 mg once daily, maximum 700 mg once daily
• CrCl <15 mL/min: 100-300 mg once daily
  • Reduce daily dose proportionally (e.g., CrCl 7.5 mL/min receives half the dose for CrCl 15 mL/min)

Hemodialysis Patients:

• Maintenance dose based on CrCl as above
• Plus supplemental post-dialysis dose of 125-350 mg after each 4-hour dialysis session 2

Critical pitfall: Gabapentin toxicity in chronic kidney disease is severely underrecognized and preventable 4. Patients with renal impairment frequently receive inappropriately high doses, leading to overt toxicity manifesting as altered mental status, myoclonus, and severe sedation. This occurs because plasma concentrations increase dramatically—up to 31-fold in severe renal impairment 3, 4.

Elderly Patient Considerations

Elderly patients require dose adjustment based on renal function, not age alone 2. However, important considerations include:

• Apparent oral clearance decreases from ~225 mL/min in patients <30 years to ~125 mL/min in those >70 years 2
• This decline is primarily explained by age-related reduction in renal function 2
• Calculate creatinine clearance using Cockcroft-Gault equation (not serum creatinine alone) 2:
  • Males: CrCl = [(140 - age) × weight in kg] / (72 × serum creatinine)
  • Females: Multiply result by 0.85

Elderly patients with multiple comorbidities are overrepresented among those experiencing gabapentin toxicity 4. Start at the lower end of the dosing range and titrate more cautiously.

Treatment Duration and Monitoring

• Initial trial: 10 weeks to assess efficacy 5
• Mandatory reassessment: At 6 months before continuing 1
• If successful: Most clinicians wean to the lowest cough-controlling dose (68.3%) or taper off completely (24.4%) after 3-6 months 6
• If cough recurs: Reinitiate at the previously effective dose (97.6% of laryngologists do this) 6

When Gabapentin Fails

If gabapentin is ineffective after adequate trial 6:

• Switch to alternative neuromodulator (amitriptyline is second-line choice, used by 91.5% of laryngologists)
• Consider superior laryngeal nerve block (24.4% of practitioners)
• Tramadol is third-line (73.2% use it, though less preferred)

Clinical Context

Gabapentin should only be used for unexplained chronic cough—defined as cough persisting >8 weeks despite guideline-based investigation and treatment trials 1. Before prescribing gabapentin, ensure patients have undergone objective testing for bronchial hyperresponsiveness and eosinophilic bronchitis, or therapeutic corticosteroid trial 1.

The evidence base consists of a single high-quality RCT showing significant improvement in cough-specific quality of life (LCQ score difference 1.80, p=0.004; NNT=3.58) 5. While the evidence grade is 2C (weak recommendation), the CHEST panel approved this recommendation with 90% consensus due to the severe quality-of-life impairment these patients experience 1.